Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.

Although inhibitors of vascular endothelial growth factor and inhibitors of epidermal growth factor receptor (EGFRi) are commonly used for the treatment of metastatic colorectal cancer (mCRC), the optimal sequencing of these agents is currently unclear. A national registry of targeted therapies was used to analyze baseline characteristics and outcomes of patients with mCRC and wild-type The cohort included 490 patients (181 patients treated with first-line EGFRi and second-line bevacizumab and 309 patients treated with first-line bevacizumab and second-line EGFRi). Median overall survival (OS) from the initiation on first-line therapy was similar for patients treated with either sequence, reaching 31.8 (95% CI 27.5-36.1) vs 31.4 months (95% CI 27.8-35.0) for EGFRi → bevacizumab vs bevacizumab → EGFRi cohort, respectively. Time from first-line initiation to progression on the second-line therapy [progression-free survival (PFS)] was 21.1 (95% CI 19.3-23.0) vs 19.3 months (95% CI 17.3-21.3) for bevacizumab → EGFRi vs EGFRi → bevacizumab cohort, respectively ( This retrospective analysis of real-world data of patients with wild-type

Déclaration de conflit d'intérêts

Disclosure TB, OF, and BM have received research funding, travel grants, and honoraria from Roche, Merck, and Amgen. AP has received honoraria and travel grants from Roche and Amgen. IK has received speakers’ honoraria from Roche, Merck, and Amgen. JF has received lecture honoraria and travel grants from Roche, Merck, Pfizer, Novartis, and Amgen. The authors declare no other conflicts of interest in this work.